// App-Quantinova.ai

P1069 : RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA

Researchers

Presenter

  • Claire Harrison

Principal Investigators

  • Prithviraj Bose

  • Ruben Mesa

  • Aaron Gerds

  • Stephen Oh

  • Jean-Jacques Kiladjian

  • Valentin Garca-Gutierrez

  • Alessandro Vannucchi

  • Christof Scheid

  • Marta Sobas

  • Srdan Verstovsek

  • Sarah Buckley

  • Karisse Roman-Torres

  • John Mascarenhas

Medical Centers

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • Guy's and St Thomas' Hospital,London,Vereinigtes Königreich

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • CTI BioPharma Corp.,Seattle,United States

  • CTI BioPharma, Seattle, WA.

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Washington University School of Medicine, St. Louis, MO

  • Guys and St Thomas NHS Trust, London, London, United Kingdom

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Guys and St Thomas NHS Trust

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Wroclaw Medical University, Wroclaw, Poland

  • Wroclaw Medical University, Wroclaw, Poland

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • University of Cologne, Cologne, DE, Germany

  • University of Cologne,Cologne,Tyskland

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • University of Cologne, Cologne, DE, Germany

  • Washington University School of Medicine, St. Louis, MO

  • Hôpital Saint-Louis, Université de Paris, INSERM,Paris,Frankrijk

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Wroclaw Medical University, Wroclaw, Poland

  • CTI BioPharma,Seattle, WA,Stati Uniti

  • Washington University School of Medicine,St. Louis, MO,Vereinigte Staaten

  • University of Cologne,Cologne,Allemagne

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • CTI BioPharma,Seattle, WA,Verenigde Staten

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • UT Health San Antonio Cancer Center, San Antonio, TX

  • University of Cologne,Cologne,Tyskland

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • CTI BioPharma,Seattle, WA,États-unis

  • University of Cologne,Cologne,Tyskland

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Washington University School of Medicine, St. Louis, MO

  • Hôpital Saint

  • UT Health San Antonio Cancer Center, San Antonio, TX

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • UT Health San Antonio Cancer Center,San Antonio, TX,Vereinigte Staaten

  • UT Health San Antonio Cancer Center,San Antonio, TX,Vereinigte Staaten

  • Washington University in Saint Louis School of Medicine, Saint Louis, Missouri, United States

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • The Tisch Cancer Institute, Icahn Sc

  • Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • University Clinic Cologne,Cologne,Deutschland

  • Azienda Ospedaliero-Universitaria Careggi, University of Florence,Florence,Italia

  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,New York,Vereinigte Staaten

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Hopital Saint-Louis, AP-HP, Universite Paris , Paris, France

  • The University of Tokyo

  • Guy's and St. Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • CTI BioPharma,Seattle, WA,Verenigde Staten

  • Washington University School of Medicine, St. Louis, MO

  • Guy's and St Thomas' NHS Foundation Trust,London,Royaume-uni

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Cleveland Clinic Taussig Cancer Institute,Cleveland,Verenigde Staten

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • UT Health San Antonio Cancer Center,San Antonio, TX,Estados Unidos

  • UT Health San Antonio Cancer Center, San Antonio, TX

  • CTI BioPharma,Seattle, WA,Estados Unidos

  • University Hospital of Cologne,Cologne,Германия

  • Hôpital Saint-Louis; Université de Paris; Inserm,Paris,France

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

  • Wroclaw Medical University,Wrocław,Польша

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of Cologne,Cologne,Tyskland

  • Wroclaw Medical University, Wroclaw, Poland

  • The University of Texas, MD Anderson Cancer Center,Houston, TX,Verenigde Staten

  • Radiotherapy Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy

Locations

  • United Kingdom

  • United States

  • Turkey

  • France

  • Spain

  • Italy

  • Germany

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Thrombocytopenia

  • Myelofibrosis

Biomarkers

  • Sustained virological response

Drug/Treatment

  • Ruxolitinib phosphate

  • Pacritinib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved